Table S1, Table S2 from A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma
Year: 2023
Type: other
Abstract: Table S1 displays second line therapies that patients pursued. Table S2 displays baseline and change (%) in plasma and cellular biomarkers.
Authors: Lipika Goyal, Hui Zheng, Thomas A. Abrams, Rebecca Miksad, Andrea J. Bullock, Jill N. Allen, Matthew B. Yurgelun, Jeffrey W. Clark, Avinash Kambadakone, Alona Muzikansky, Michelle Knowles, Aralee Galway, Anthony J. Afflitto, Caroline F. Dinicola, Eileen Regan, Tai Hato, Emilie Mamessier, Kohei Shigeta, Rakesh K. Jain, Dan G. Duda, Andrew X. Zhu
Language: English
Subfield: Hepatology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361962471